Modification of IL-7 for anticancer therapy. (A) Adjuvant treatment of IL-7 and its receptor complex enhances the potency of cancer vaccines. (B) Intratumoral administration of IL-7-transduced DCs (DC-AdIL-7) induces direct IL-7 signals in the tumor site. (C-F) Engineered IL-7 complexes with enhanced bioactivity. (C) IL-7 complexed with IL-7Rα-Fc. (D) IL-7 complex with a monoclonal antibody clone M25. (E) IL-7 fused with the Fc region of the antibody. (F) IL-7 fused to a hybrid Fc (IgD/IgG4) has a prolonged serum half-life without cytotoxicity on target cells. Figure created with BioRender.com.
